st-teresa-medical-7x4.jpg

St. Teresa Medical, Inc. Announces Appointment of Richard Guyer, M.D. to Scientific Advisory Board

Posted On September 6, 2016 By OrthoSpineNews In Spine /  

ST. PAUL, Minn., Sept. 6, 2016 /PRNewswire-USNewswire/ — St. Teresa Medical, Inc. today announced the appointment of Richard Guyer M.D. to its scientific advisory board.  Dr. Guyer is a board certified orthopedic spine surgeon and one of the founders of Texas Back Institute and serves as its President.  He also serves as the Chairman of the Board of Directors for the Texas Back Institute Research Foundation and has been Director of the Spine Surgery Fellowship program since its inception in 1986.

Dr. Guyer did his medical school and residency training at the University of Pennsylvania School of Medicine and completed two spine fellowships, one at Case Western Reserve University with Henry Bohlman, M.D. in Cleveland, Ohio and the other with Leon Wiltse, M.D. in Long Beach, California.  He holds many patents in spine surgery and has published over 100 peer-reviewed articles and 45 chapters presenting his research at national and international spine conferences.  While the majority of the research work has dealt with the diagnosis and treatment of painful degenerative spinal conditions, he is also one of the pioneers in minimally invasive surgery and lumbar and cervical disc replacement.   In the early 1980s he worked with his former mentor Parviz Kambin who pioneered endoscopic discectomy.   In 2000 he performed one of the first disc lumbar disc replacements in the USA and has been an investigator in nearly a dozen U.S. IDE studies of both cervical and lumbar disc replacements.  He continues to research and publish in this area as well as in motion preservation and minimally invasive treatments.

Dr. Guyer has been very active with various spine societies including North American Spine Society (NASS), Cervical Spine Research Society (SSRS), International Society for the Study of the Lumbar Spine (ISSLS), and International Society for the Advancement of Spine Surgery (ISASS) serving as President of NASS during the 2006-2007 year and various committees of the ISASS.  He was recently appointed to the board of directors of the American Board of Spinal Surgery.

Philip Messina, President and CEO said, “We are very pleased to welcome Dr. Guyer to our Scientific Advisory Board.  He is considered to be among the top spine surgeons in the world.  We could not be more pleased to have him on board. “

  1. Timothy Floyd, MD, Chief Scientific Officer and Chair of the Scientific Advisory Board said, “Dr. Guyer is a world leader in cutting edge spine surgery and techniques.  His counsel, as we move into our global clinical trial on SURGICLOT will be important.”

About St. Teresa

St. Teresa Medical, Inc.®, based in St. Paul, MN., is a medical-device company developing SURGICLOT®, a new unique dissolvable hemostatic dressing for use during orthopedic surgery.  SURGICLOT® is uniquely fabricated from nanoscale electro-spun dextran fibers infused with fibrinogen and thrombin.  SURGICLOT® works by supplementing and enhancing the body’s natural clotting mechanism.  SURGICLOT® utilizes thrombin and fibrinogen obtained from human sources.

For more information, see www.StTeresaMedical.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/st-teresa-medical-inc-announces-appointment-of-richard-guyer-md-to-scientific-advisory-board-300322887.html

SOURCE St. Teresa Medical, Inc.

Read More
00465-master-6.jpg

Medtronic, Zimmer Biomet Enter 2-level Cervical Disc and Robotic Markets

Posted On September 2, 2016 By OrthoSpineNews In Robotics, Spine /  

September 1, 2016 – By  Carolyn LaWell

Disc Replacement

Zimmer Biomet’s $1 billion acquisition of LDR and its Mobi-C cervical disc assets and Medtronic’s FDA Premarket Approval for the Prestige LP 2-level application changed the game in the U.S. 2-level cervical disc replacement arena.

Mobi-C had been the only 2-level disc approved on the U.S. market. Prior to Zimmer Biomet’s purchase of the technology, LDR was able to expand reimbursement coverage, update label claims and publish peer-reviewed papers that resulted in Mobi-C’s sales growth, which increased 80% in 2015 vs. 2014.

Further, in April 2016, LDR reported that Mobi-C had surpassed $100 million in cumulative U.S. revenue since its 2013 launch. Half of the Mobi-C units sold address 1-level indications and half are for 2-level indications.

The acquisition of LDR allows Zimmer Biomet to increase its share of the worldwide spine market from 4% to 5%, according to ORTHOWORLD estimates. While the purchase also expands Zimmer Biomet’s traditional cervical and lumbar offerings, Mobi-C is presumably the technology that attracted Zimmer Biomet to LDR, primarily.

Medtronic’s entry into the 2-level market is expected to put competitive pressure on Zimmer Biomet’s purchase. The 2-level discs will be sold in a small market that faces a lack of reimbursement, compared to 1-level discs and fusion. To dive into specifics, >50 million lives are covered for Mobi-C’s 2-level procedure. The total artificial disc market is expected to reach ~$275 million in 2016, according to estimates in the ORTHOWORLD report, Cervical and Lumbar Artificial Disc Profiles.

 

READ THE REST HERE

 

Read More